|
Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.
|
| | | Contact Information | |
Address: |
40 Landsdowne St.
Cambridge, MA 02139
| | Phone: | 617-679-7000 | | Fax: | 617-374-7788 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Kenneth E. Weg
| | • |
President, CEO, and Director:
Deborah Dunsire
| | • |
SVP Finance and CFO:
Marsha H. Fanucci
|
|
|
